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Original ArticleTransition of a Clinical Practice to Use of Subdural Drains after Burr Hole Evacuation of
Chronic Subdural Hematoma: The Helsinki ExperiencePihla Tommiska1, Kimmo Lo¨nnrot1, Rahul Raj1, Teemu Luostarinen2, Riku Kivisaari1-BACKGROUND: A number of randomized controlled tri-
als have shown the benefit of drain placement in the
operative treatment of chronic subdural hematoma (CSDH);
however, few reports have described real-life results after
adoption of drain placement into clinical practice. We
report the results following a change in practice at Hel-
sinki University Hospital from no drain to subdural drain
(SD) placement after burr hole craniostomy for CSDH.
-METHODS: We conducted a retrospective observational
study of consecutive patients undergoing burr hole cra-
niostomy for CSDH. We compared outcomes between a 6-
month period when SD placement was arbitrary (Julye
December 2015) and a period when SD placement for 48
hours was routine (JulyeDecember 2017). Our primary
outcome of interest was recurrence of CSDH necessitating
reoperation within 6 months. Patient outcomes, infections,
and other complications were assessed as well.
-RESULTS: A total of 161 patients were included,
comprising 71 (44%) in the drain group and 90 (56%) in the
non-drain group. There were no significant differences in
age, comorbidities, history of trauma, or use of antith-
rombotic agents between the 2 groups (P > 0.05 for all).
Recurrence within 6 months occurred in 18% of patients in
the non-drain group, compared with 6% in the drain group
(odds ratio, 0.28; 95% confidence interval, 0.09e0.87;
P [ 0.028). There were no differences in neurologic out-
comes (P [ 0.72), mortality (P [ 0.55), infection rate
(P [ 0.96), or other complications (P [ 0.20).Key words
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- Neurosurgery
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- Surgery
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e614 www.SCIENCEDIRECT.com WORLD NE-CONCLUSIONS: The change in practice from no drain to
use of an SD after burr hole craniostomy for CSDH effec-
tively reduced the 6-month recurrence rate with no effect
on patient outcomes, infections, or other complications.INTRODUCTIONhe incidence of chronic subdural hematoma (CSDH) ranges
from 1.7 to 18 per 100,000 population. In patients age >65Tyears, this rate increases to 58 per 100,000, making CSDH
one of the most common neurosurgical conditions.1,2 Most physi-
cians would agree that nonsurgical treatment is recommended for
asymptomatic patients with a small CSDH.3 For symptomatic CSDH,
burr hole evacuation has become the most preferred treatment
method,4,5 producing rapid resolution of symptoms with a short
duration of hospitalization. Other surgical options, such as the use of
2 burr holes, twist drill craniostomy, and even craniotomy in selected
patient populations, are also available to treat CSDH.2,3
To date, there is a lack of consensus regarding the optimal
surgical technique.6 Even among Scandinavian centers, surgical
techniques differ.7 Reported recurrence rates vary from 3% to
33% and may depend on both treatment- and patient-related
factors.8-11 Numerous studies have indicated that the recurrence
rate is most effectively reduced by placement of either a subdural
drain (SD) or a subgaleal drain.12-16 In a randomized controlled
trial (RCT) reported by Santarius et al,16 the placement of an SD
after burr hole evacuation reduced the rate of CSDH recurrence
from 24% to 9%.OR: Odds ratio
RCT: Randomized controlled trial
SD: Subdural drain
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PIHLA TOMMISKA ET AL. TRANSITION TO USE OF SDS AFTER EVACUATION OF CSDHAlthough the use of an SD has been reported to reduce
recurrence rates, some studies still dispute this conclusion.11,17
The analysis of numerous questionnaire surveys points to an
evidenceepractice gap in the use of drains, because not all neu-
rosurgeons place them regularly.4,18-22 Despite reported evidence
supporting the beneﬁts of drain placement, drain use in routine
practice at the Department of Neurosurgery of Helsinki University
Hospital was arbitrary until April 1, 2017, when consistent man-
agement of CSDH with an SD was established in our clinic.
Owing to the stricter inclusion and exclusion criteria of RCTs,
the beneﬁts of drain use as shown by such trials might not
necessarily reﬂect the realities of the clinical setting.23
Nonetheless, there remains a need for real-life observational
studies to conﬁrm the data from RCTs.24 Thus, in the present
study, we aimed to assess whether the change in clinical
practice to incorporate the routine use of SDs has resulted in a
lower recurrence rate. Speciﬁcally, our primary goal was to
conﬁrm whether patients treated with postoperative drains
experienced lower recurrence rates compared with those who
did not receive drains. The secondary aim was to compare the
changes in hematoma size, complications, and patient outcomes
between the 2 groups.Figure 1. Flow chart displaying the inclusion and
exclusion criteria and the formation of study groups.
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Ethical Considerations
The Ethics Committee of Helsinki University Hospital approved
this study and waived the requirement for informed consent (HUS
1799/2018).Study Setting and Data Collection
On April 1, 2017, the use of an SD after burr hole craniostomy for
CSDH evacuation became routine practice at our clinic. Thus, to
assess the effect of SD use on 6-month recurrence risk, we chose
time periods to represent the pre-drain era (JulyeDecember 2015)
and the drain era (JulyeDecember 2017). During these periods, we
assessed all patients who underwent surgery for CSDH at the
Department of Neurosurgery of Helsinki University Hospital. The
non-drain group included patients from the pre-drain era, and
from this group, we excluded all patients treated with a drain. The
SD group included patients from the drain era, and from this
group, we excluded those not treated with an SD and also those
treated with a type of drain other than an SD. We also excluded
patients who had undergone previous intracranial surgery for any
reason, as well as those with shunts for cerebrospinal ﬂuidCSDH, chronic subdural hematoma; SIH, spontaneous
intracranial hypotension.
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Table 1. Baseline Patient Characteristics
Variable
All Patients
(N [ 161)
Drain
(N [ 71)
Non-Drain
(N [ 90)
P
Value
Age (years), median (range) 77 (46e95) 78 (57e93) 77 (46e95) 0.77
Women, n (%) 51 (32) 21 (30) 30 (33) 0.61
History of trauma, n (%) 131 (81) 62 (87) 69 (77) 0.08
Premorbid mobility, n (%) 0.40
Independent 119 (75) 51 (74) 68 (76)
Stick 6 (4) 3 (4) 3 (3)
Zimmer frame 24 (15) 12 (17) 12 (13)
Wheelchair 5 (3) 3 (4) 2 (2)
Bed-bound 4 (3) 0 4 (4)
Premorbid residence, n (%) 0.52
Independent 119 (74) 50 (70) 69 (78)
Carer 23 (14) 13 (18) 10 (11)
Residential 15 (9) 6 (8) 9 (10)
Nursing 3 (2) 2 (3) 1 (1)
Medical history, n (%)
Dementia 35 (22) 16 (23) 19 (21) 0.83
Arrhythmia 57 (35) 23 (32) 34 (38) 0.48
Cerebrovascular accident 40 (25) 19 (27) 21 (23) 0.62
Hypertension 110 (68) 45 (63) 65 (72) 0.23
Ischaemic heart disease 40 (25) 18 (25) 22 (24) 0.89
DVT or PE* 3 (2) 0 3 (3) 0.26
COPD 7 (4) 5 (7) 2 (2) 0.24
Diabetes 38 (24) 16 (23) 22 (24) 0.78
Heart valve prosthesis 4 (2) 1 (1) 3 (3) 0.63
Antithrombotic drug history,
n (%)y
107 (66) 48 (68) 59 (66) 0.78
Anticoagulantsy 56 (35) 26 (37) 30 (33) 0.66
Warfarin 35 (22) 14 (20) 21 (23) 0.58
LMWH 12 (7) 4 (6) 8 (9) 0.43
DOAC 12 (7) 9 (13) 3 (3) 0.025
Antiplateletsy 58 (36) 25 (35) 33 (37) 0.85
Acetylsalicylic acid,
dipyridamole
52 (32) 21 (30) 31 (34) 0.51
Clopidogrel, ticagrelor 12 (7) 6 (8) 6 (7) 0.67
Admission mRS score, median
(IQR)
3 (2e4) 3 (2e4) 3 (2e4) 0.61
Admission mRS score, n (%) 0.98
0 2 (1) 1 (1) 1 (1)
1 7 (4) 3 (4) 4 (4)
2 39 (24) 15 (21) 24 (27)
Continues
Table 1. Continued
Variable
All Patients
(N [ 161)
Drain
(N [ 71)
Non-Drain
(N [ 90)
P
Value
3 39 (24) 18 (25) 21 (23)
4 47 (29) 22 (31) 25 (28)
5 27 (17) 12 (17) 15 (17)
Preoperative hemiparesis, n (%) 78 (48) 34 (48) 44 (49) 0.90
Preoperative dysphasia, n (%) 52 (33) 26 (37) 26 (29) 0.32
Data on mobility are missing for 3 patients and data on residence and dysphasia are
missing for 1 patient.
DVT, deep venous thrombosis; PE, pulmonary embolism; COPD, chronic obstructive pul-
monary disease; LMWH, low molecular weight heparin; DOAC, direct oral anticoag-
ulant; mRS, modified Rankin Scale; IQR, interquartile range.
*Medication used within 12 months.
yBefore detection of subdural hematoma.
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PIHLA TOMMISKA ET AL. TRANSITION TO USE OF SDS AFTER EVACUATION OF CSDHdiversion or subdural hematomas treated with other methods
(e.g., subgaleal drain, IRRAﬂow catheter) (Figure 1).
All data concerning patients’ medical history, imaging, and
treatment are stored in Helsinki University Hospital’s electronic
health record (EHR). We retrospectively reviewed and analyzed
patients’ EHR and preoperative and postoperative head computed
tomography (CT) scans or brain magnetic resonance imaging
(MRI) images. From the EHR, we obtained patients’ baseline and
follow-up data concerning mobility and morbidity, history of head
trauma in the preceding 12 months, most prominent symptom
causing disability, modiﬁed Rankin Scale (mRS) score,25 medical
history, and presence of limb weakness or dysphasia. To ensure
coherency, a single investigator assessed all clinical data.
Two senior neurosurgeons analyzed all the imaging data from
CT and MRI scans. We deﬁned the subdural collection as pre-
dominantly hypodense, isodense, or mixed by comparing the
density of the collection with the adjacent brain.26 In addition, we
measured the maximum transition of the anatomic midline
structures from the midline and determined the midline shift.
On bilaterally operated hematomas, we recorded which side
caused the midline shift. We also measured the width, length,
and height of the collection and calculated the volume of the
hematoma using the ABC/2 formula.27 CSDH volume reduction
was analyzed by comparing preoperative and postoperative CT
or MRI images. We also recorded the extent of basal cistern
effacement, patency of cortical sulci, and presence of contusions.Burr Hole Craniostomy Procedure
As a routine, all burr hole craniostomies at Helsinki University
Hospital are performed under local anesthesia, often combined
with intravenous sedation with benzodiazepines and/or opioids
during the operation. Here general anesthesia is used only if the
neurosurgeon or the anesthesiologist considers it unsafe to
perform the procedure under local anesthesia (applicable to only 1
patient in our present cohort).
Typically, the surgeon drills a 14-mm burr hole over the maximum
convexity of the hematoma. In the case of an expansive bilateral
hematoma, the surgeon operates on both sides. After opening theUROSURGERY, https://doi.org/10.1016/j.wneu.2019.05.230
Table 2. Preoperative Imaging Characteristics
Variable All Patients (N[ 161) Drain (N [ 71) Non-Drain (N [ 90) P Value
Side, n (%) 0.39
Left 70 (44) 34 (48) 36 (40)
Right 57 (35) 21 (30) 36 (40)
Bilateral 34 (21) 15 (22) 18 (20)
Total hematoma volume, cm3, median (IQR) 137 (93e175) 149 (99e170) 131 (92e178) 0.54
Unilateral (N [ 127) (N [ 55) (N [ 72)
Hematoma density, n (%) 0.90
Hypodense 32 (25) 13 (24) 19 (26)
Isodense 10 (15) 9 (16) 10 (14)
Mixed 43 (60) 33 (60) 43 (60)
Midline shift, mm, median (IQR) 7 (4e10) 7 (3e10) 7 (4e10) 0.92
Hematoma thickness, mm, median (IQR) 22 (17e25) 23 (19e27) 20 (15e24) 0.007
Hematoma volume, cm3, median (IQR) 126 (88e155) 131 (86e157) 116 (88e151) 0.32
Cortical sulci, n (%) 0.07
Open 10 (8) 3 (6) 7 (10)
Compressed 24 (19) 6 (10) 18 (25)
Closed 93 (73) 46 (84) 47 (65)
Bilateral (N [ 34) (N [ 16)* (N [ 18)
Midline shift, mm, median (IQR) 2 (0e4) 0 (0e4) 3 (2e4) 0.08
Side causing midline shift, n (%) 0.13
Left 13 (38) 4 (25) 8 (45)
Right 9 (27) 3 (19) 6 (33)
No midline shift 12 (35) 9 (56) 4 (22)
Total hematoma volume (cm3), median
(IQR)
206 (159e254) 186 (151e241) 239 (184e261) 0.10
Both sides separately (N [ 68) (N [ 27) (N [ 41)
Hematoma density, n (%) 0.74
Hypodense 12 (18) 5 (19) 7 (17)
Isodense 22 (32) 10 (37) 12 (29)
Mixed 34 (50) 12 (44) 22 (54)
Hematoma thickness, mm, median (IQR) 18 (15e21) 19 (16e22) 17 (14e21) 0.33
Hematoma volume, cm3, median (IQR) 108 (71e130) 100 (76e123) 108 (67e145) 0.74
Cortical sulci, n (%) 0.91
Open 6 (9) 2 (7) 4 (10)
Compressed 21 (31) 9 (33) 12 (29)
Closed 41 (60) 16 (60) 25 (61)
Neither basal cistern effacement nor contusion was observed in any patient.
IQR, interquartile range.
*Patients treated with a subdural drain unilaterally or bilaterally.
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PIHLA TOMMISKA ET AL. TRANSITION TO USE OF SDS AFTER EVACUATION OF CSDHdura, the surgeon washes the subdural collection with warm (body
temperature) Ringer’s lactate saline until the rinsing appears clear,
and decides whether or not to insert an SD. The SD used in this study
was a 10 F Spiegelberg Ventricular Catheter (length 270 mm, inner
diameter 1.9 mm, outer diameter 3.3 mm; NeoNordic, Odense,
Denmark), made of radiopaque polyurethane. The surgeon tunnels
the drain under subgaleal skin approximately 5 cm from the incision
and links it to a ventricular drainage bag with a connector. The
drainage bag is positioned at bed level and is routinely removed after
48 hours. We do not use postoperative prophylactic antibiotics
routinely.
In 2015, drain use was not mandatory in our clinic, and the use
of SDs and subgaleal drains was sporadic. At the beginning of
2017, a new administrative guideline was enforced, and drain use
became a requirement, except in cases where the surgeon believes
that a drain would compromise patient safety. SDs are routinely
left in place for 48 hours, and patient mobilization is allowed
during this time.
Follow-Up and Outcome Measures
At approximately 4e6 weeks postsurgery, follow-up was
completed for all patients in the Helsinki Metropolitan Area at an
outpatient clinic. For patients living outside this area, a recom-
mendation for follow-up was made to their local hospital. For the
follow-up, a routine head CT was recommended. If residual he-
matoma or symptoms warranted further assessment, the patient
was invited monthly for further follow-ups until the collection or
symptoms resolved.
Our primary outcome was CSDH recurrence necessitating reop-
eration within 6 months. Because no other institution in the catch-
ment area of Helsinki University Hospital performs intracranialFigure 2. Most prominent symptom c
e618 www.SCIENCEDIRECT.com WORLD NEoperations, all patients requiring reoperation are referred to this
hospital. We consider reoperation in patients with a new CT scane
veriﬁed CSDH with recurrent neurologic symptoms or with a recur-
rent hematoma of similar or larger size as the primary CSDH.
Our secondary outcomes included neurologic outcome within 7
days and then at 6 months after the primary operation (as
measured by the mRS), 30-day and 6-month mortality, length of
stay in the neurosurgical ward, and development of postoperative
infections and other complications. A favorable postoperative
neurologic outcome was deﬁned as an mRS score of 0e3, and an
unfavorable outcome was deﬁned as an mRS score of 4e6. We
also recorded all postoperative complications and determined
whether they were related to the operation. In addition, we ob-
tained dates of deaths through the Finnish Population Registry
(available to all Finnish citizens).
Statistical Analyses
We compared categorical variables using the c2 test, adjusting the
Bonferroni method and using Fisher’s exact test when appro-
priate. We used the ShapiroeWilk test to evaluate continuous
variables for normality, the ManneWhitney U test to compare
nonparametric data, and the t test to compare normally distributed
data. Testing was also performed to identify any differences in
baseline characteristics between patients in the SD and non-drain
groups. Binary logistic regression analysis was used to identify
associations between variables and the risk of recurrence within 6
months, with adjustments made for differences in baseline char-
acteristics between the groups (reported as odds ratios [ORs] and
95% conﬁdence intervals [CIs]). We used KaplaneMeier curves to
show differences in time to recurrence within 6 months between
the SD and non-drain groups. We considered a P value <0.05 toausing disability to the patient
UROSURGERY, https://doi.org/10.1016/j.wneu.2019.05.230
Table 3. Univariable Logistic Regression Analysis for Primary and Secondary Outcomes in the Drain and Non-Drain Groups
Outcome Drain (N [ 71) Non-Drain (N [ 90) OR (95% CI) P Value
Recurrence within 6 months, n/N (%)
All 4/71 (6) 16/90 (18) 0.28 (0.09e0.87) 0.028
Unilateral CSDHs 3/55 (5) 12/72 (17) 0.29 (0.08e1.08) 0.07
Bilateral CSDHs 1/16 (6) 4/18 (22) 0.23 (0.02e2.35) 0.22
Postoperative mRS 0e3, n/N (%)
At 7 days 40/71 (56) 52/90 (58) 0.94 (0.50e1.77) 0.85
At 6 months 35/55 (64) 48/72 (67) 0.88 (0.42e1.83) 0.72
Mortality, n/N (%)
At 30 days 1/71 (1) 6/90 (7) 0.20 (0.02e1.70) 0.14
At 6 months 8/71 (11) 13/90 (14) 0.75 (0.29e1.93) 0.55
Hospital stay in neurosurgical unit, days, median (IQR) 3 (2e5) 2 (1e4) NA 0.17k
Further care needed, n/N (%) 45/71 (63) 53/90 (59) 1.21 (0.64e2.29) 0.56
Postoperative complications within 7 days, n/N (%)* 8/71 (11) 5/90 (6) 2.16 (0.67e6.91) 0.20
Postoperative infections, n/N (%)y
Within 30 days 8/71 (11) 11/90 (12) 0.91 (0.35e2.40) 0.85
Within 6 months 16/56 (29) 20/71 (28) 1.02 (0.47e2.22) 0.96
Worse mobility at 6 months, n/N (%)z 10/48 (21) 14/59 (24) 0.85 (0.34e2.12) 0.72
Hematoma volume reduction (cm3), mean (SD)x 103 (56) 72 (60) NA 0.005k
Percent volume reduction, mean (SD)x 70 (31) 50 (39) NA 0.005k
ORs are calculated for binary outcomes using logistic regression. An OR <1 indicates that a subdural drain is associated with a lower probability for the specific outcome and an OR >1
indicates association with a greater probability.
OR, odds ratio; CI, confidence interval; CSDH, chronic subdural hematoma; mRS, modified Rankin Scale; IQR, interquartile range; NA, not applicable; SD, standard deviation.
*Postoperative complications included cerebral infarction, intracerebral hemorrhage, wound bleeding, epileptic seizure, unintended drain removal, cardiac failure, pulmonary embolism, and
epidural hematoma.
yPostoperative infections included urinary tract infection, pneumonia, soft tissue infection, shingles, upper respiratory infection, erysipelas, gastroenteritis, and nonspecific infection.
zExcluding patients dying before 6 months.
xMissing for 44 of 161 patients (27%).
kCalculated using the nonparametric ManneWhitney U test.
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logistic regression analysis assessing the association between
drain use and recurrence within 6 months, adjusting for age, sex,
preoperative neurologic deﬁcit, and use of antithrombotic medi-
cation. All analyses were done using SPSS 25.0 for macOS (IBM,
Armonk, New York, USA).
RESULTS
Baseline Characteristics
Our study cohort comprised 161 patients, including 71 (44%) in
the SD group and 90 (56%) in the non-drain group (Figure 1).
There were no signiﬁcant differences in baseline characteristics
between the 2 groups (Table 1). Similarly, no substantial
differences were seen between patients treated in 2017 with SDs
and those treated in 2017 without drains (Supplementary
Table 1). The only signiﬁcant baseline ﬁnding was thicker
hematomas in the SD group (median, 23 mm vs. 20 mm;
P ¼ 0.007) (Table 2).WORLD NEUROSURGERY 129: e614-e626, SEPTEMBER 2019ReasonscitedfornotplacinganSDin2017includedimmediatebrain
expansion (n ¼ 11), membrane loculations (n ¼ 3), antithrombotic
treatment(n¼2), infection(n¼1),headwoundoperation(n¼1),anda
surgeon’s belief that inserting a drain would be unsafe (n¼ 1).
The main presenting symptoms are shown in Figure 2.
Altogether, 53% of the patients had a motor deﬁcit, presenting
as gait disturbance or limb weakness.Rate of CSDH Recurrence
The 6-month CSDH recurrence rate was 6% (n/N ¼ 4/71) in the SD
group and 18% (n/N ¼ 16/90) in the non-drain group (P ¼ 0.028).
Because there were no differences in patient baseline character-
istics between the 2 groups, we assessed the association between
SD use and risk of recurrence within 6 months using univariable
logistic regression analyses. SD use was associated with an OR of
0.28 (95% CI, 0.09e0.87) for recurrence within 6 months
compared with no drain use. In patients with unilateral CSDH, the
6-month recurrence rate was reduced from 17% (n/N ¼ 12/72) inwww.journals.elsevier.com/world-neurosurgery e619
Table 4. Factors Associated with Recurrence of Chronic Subdural Hematomas Requiring Reoperation within 6 Months
Variable
No Recurrence
(N [ 141)
Recurrence
(N [ 20) OR (95% CI) P Value
Age (years), median (range) 78 (46e95) 77 (56e90) 0.98 (0.94e1.02) 0.33
Neurologic deficit (hemiparesis or dysphasia), % 60 45 0.54 (0.21e1.38) 0.20
History of trauma, % 84 65 0.36 (0.13e1.01) 0.051
Antithrombotic drug history, %* 65 75 1.60 (0.55e4.66) 0.39
Anticoagulants, %* 33 50 2.07 (0.80e5.31) 0.13
Antiplatelets, %* 38 25 0.55 (0.19e1.61) 0.28
Preoperative mRS 0e3, % 53 60 1.32 (0.51e3.43) 0.57
Preoperative mRS 4e5, % 47 40 0.76 (0.29e1.97) 0.57
Unilateral hematoma, % 79 75 0.78 (0.26e2.31) 0.65
Bilateral hematoma, % 21 25 1.29 (0.43e3.83) 0.65
Midline shift, mm, median (IQR)y 7 (3e10) 9 (4e11) 1.06 (0.95e1.19) 0.30
Mixed-density clot, % 61 42 0.47 (0.18e1.25) 0.13
Subdural drain, % 48 20 0.28 (0.09e0.87) 0.028
Odds ratios calculated using univariable logistic regression. An odds ratio over 1 indicates that the specific variable is associated with a higher probability for recurrence and vice versa.
OR, odds ratio; CI, confidence interval; mRS, modified Rankin scale; IQR, interquartile range.
*Before detection of subdural hematoma.
yExcluding bilateral hematomas.
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0.06). In patients with bilateral CSDH, the 6-month recurrence
rates were 22% in the non-drain group (n/N ¼ 4/18) and 6% in the
drain group (n/N ¼ 1/16) (P ¼ 0.22). All recurrences were treated
by burr hole craniostomy (Table 3).
The results of our analysis of factors possibly associated with 6-
month recurrence of CSDH are presented in Table 4. Apart from
SD use, no other risk factors were signiﬁcantly associated with
recurrence. In the post hoc logistic regression analysis,
adjusting for age, sex, preoperative neurologic deﬁcit, and use
of antithrombotic medication, SD use remained independently
associated with a reduced risk of 6-month recurrence (OR, 0.27;
95% CI, 0.08e0.85; P ¼ 0.025).
Before being diagnosed with CSDH, 66% of the patients
(n/N ¼ 107/161) were receiving some type of antithrombotic medica-
tion. Preoperative use of antithrombotic medication was not associ-
ated with CSDH recurrence. Postoperatively, antithrombotic
medication was resumed before the ﬁrst control (4e6 weeks after the
operation) in 28%of the patients (n/N¼ 29/102), 17% (n¼ 5) ofwhom
had a recurrent CSDH. One of these 5 patients was treated with an SD
and the other 4 were treated without drain in the primary operation.
Figure 3 presents a KaplaneMeier curve of differences between
the SD and non-drain groups in the time to 6-month recurrence
and the risk of 6-month recurrence. Notably, the risk of recurrence
was greatest in the ﬁrst 30 days after the procedure, after which it
remained low throughout the follow-up period.
Secondary Outcomes
There were no signiﬁcant between-group differences in immediate
postoperative mRS score (P ¼ 0.85), 6-month mRS scoree620 www.SCIENCEDIRECT.com WORLD NE(P ¼ 0.72), 30-day mortality (P ¼ 0.14), 6-month mortality
(P ¼ 0.55), hospital length of stay (P ¼ 0.17), need for further care
(P ¼ 0.56), infection within 30 days (P ¼ 0.85) or within 6 months
(P¼ 0.96), or other complications (P ¼ 0.20) (Table 3). Among the
secondary outcomes, only volume reduction differed signiﬁcantly
between the SD and non-drain groups (mean volume reduction,
70% vs. 50%; P ¼ 0.005). Postoperative infections and other
complications are presented in Supplementary Table 2. All
complications were diagnosed within 7 days postoperatively. Of
note, no patient developed wound infection, meningitis, or
intracranial empyema.
DISCUSSION
In this study, we have shown that the transition to consistent use
of an SD after burr hole craniostomy for CSDH in a real-world
clinical setting (Helsinki University Hospital) reduced the 6-
month recurrence rate from 18% to 6% with no increase in the
rates of infections or complications. SD use did not affect patient
outcome but corresponded to a notable decrease in CSDH volume.
Furthermore, we showed that CSDH recurrence is greatest within
the ﬁrst 30 days after treatment and decreases thereafter. Our
ﬁndings are in line with recurrence rate reductions reported in
numerous RCTs.16,28-30
Our ﬁndings indicating a predominance of elderly patients and
those with a recent history of head trauma (81%), as well as a sex
ratio in favor of males (68%), are also in line with previous re-
ports.31-34 CSDH is common in elderly patients and has a major
impact on their independence. Numerous studies have reported a
high rate of functional dependency, even in patients who have
undergone surgery.31,33,35 In a study reported by Leroy et al.,33 theUROSURGERY, https://doi.org/10.1016/j.wneu.2019.05.230
Figure 3. Kaplan-Meier curve showing differences in time to 6-month
recurrence and risk of 6-month recurrence between patients in the
subdural drain and non-drain groups. Of patients in the non-drain group,
18% had a recurrence, most often occurring within the first 30 days
following treatment. Of patients in the subdural drain group, 6% had a
recurrence.
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functional outcome. In our study, the median patient age was 78
years in the drain group and 77 years in the non-drain group.
Before diagnosis, 75% of our patients had been walking inde-
pendently, and 70% of the drain group and 78% of the non-drain
group were living independently. At 6 months after treatment,
only 80% had recovered to walk independently. In this study, we
were unable to reproduce the reduction of mortality rate by drain
usage reported by Santarius et al.16 Furthermore, only 64% of
patients recovered to a good mRS score, compared with 84%
reported by Santarius et al.16 These differences may be due to
the slightly older age of our patients, with the attendant higher
morbidity and greater need for assistance.
The use of antithrombotic medication is a pressing issue in
patients with CSDHs. In a recent meta-analysis,36 both
anticoagulation and antiplatelet therapy were associated with a
greater risk of recurrence. In our study, two-thirds of patients
were on some sort of antithrombotic medication. We did not ﬁnd
any association between preoperative use of antithrombotic
medication and recurrence risk. Furthermore, antithrombotic
medication was resumed before the ﬁrst follow-up (4e6 weeks
postoperatively) in 28% of the users, only 17% of whom had a
recurrent CSDH necessitating reoperation. The number of re-
currences in the antithrombotic users was too low to allow for any
more detailed statistical analysis. Regardless, these low numbersWORLD NEUROSURGERY 129: e614-e626, SEPTEMBER 2019suggest that excessive caution regarding restarting of antith-
rombotic medication after CSDH evacuation might not be as
important as previously thought. More studies on this topic are
needed, however.
Our results were derived from a retrospective analysis, which is
prone to well-known limitations, and thus caution in interpreta-
tion is advised. As mentioned earlier, in the Helsinki catchment
area, all patients requiring reoperation are sent to Helsinki Uni-
versity Hospital, the only institution in the region that performs
such operations. This allowed us to obtain complete data in terms
of 6-month recurrence and mortality rates. Furthermore, we ob-
tained 6 months of follow-up data on mRS scores for 79% of
patients, on mobility for 76%, and on infection rate for 75%.
In the operative management of CSDH, numerous unsettled
intraoperative and postoperative factors contribute to outcomes.
At Helsinki University Hospital, we routinely perform the pro-
cedures under local anesthesia, whereas some institutions favor
general anesthesia.16 We typically use 1 burr hole, whereas some
centers prefer 2 burr holes.37 We use SDs rather than other
drainage methods, such as active SDs, drains with continuous
irrigation and drainage, or subgaleal drains. None of these
methods has been shown to be superior to the others.7,9,15 We
provide intraoperative irrigation until ﬂuid is clear. Some studies
have reported that irrigation results in better outcomes,9 whereas
others have shown no disadvantage to placing a drain without
irrigation.5,38,39 We keep the drain in place for 48 h, although
12e18 hours of drainage has been reported.7 We allow patient
mobilization during drain treatment, whereas some centers opt
for bed rest.11,40
Although we observed a reduced rate of 6-month recurrence
after the initiation of SD use, we note that several factors related to
perioperative treatment may affect the risk of recurrence. Evidence
in favour of drain use is increasingly convincing; however, the
need for further research in the treatment of CSDH remains.CONCLUSION
SD use after burr hole craniostomy for CSDH has been shown to
signiﬁcantly reduce the risk of recurrence without affecting patient
outcome, infections or complications. More research is needed to
identify other treatment-related factors that might further reduce
this risk.ACKNOWLEDGMENTS
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PIHLA TOMMISKA ET AL. TRANSITION TO USE OF SDS AFTER EVACUATION OF CSDHAPPENDIXSupplementary Table 1. Baseline Characteristics of the Drain and Non-Drain Groups in 2017
Variable Drain (N [ 71) Non-Drain (N [ 26) P Value
Age (years), median (range) 78 (57e93) 78 (42e102) 0.67
Women, n/N (%) 21/71 (30) 9/26 (35) 0.63
History of trauma, n/N (%) 62/71 (87) 18/26 (69) 0.07
Premorbid mobility, n/N (%) 0.58
Independent 51/69 (74) 17/26 (65)
Stick 3/69 (4) 1/26 (4)
Zimmer frame 12/69 (17) 5/26 (19)
Wheelchair 3/69 (4) 3/26 (12)
Premorbid residence, n/N (%) 0.92
Independent 50/71 (70) 20/26 (77)
Carer 13/71 (18) 5/26 (19)
Residential 6/71 (8) 1/26 (4)
Nursing 2/71 (3) 0/26
Medical history, n/N (%)
Dementia 16/71 (23) 2/26 (8) 0.14
Arrhythmia 23/71 (32) 7/26 (27) 0.61
Cerebrovascular accident 19/71 (27) 9/26 (35) 0.45
Hypertension 45/71 (63) 18/26 (69) 0.59
Ischemic heart disease 18/71 (25) 7/26 (27) 0.88
DVT or PE* 0/71 1/26 (4) 0.27
COPD 5/71 (7) 1/26 (4) 0.99
Diabetes 16/71 (23) 8/26 (31) 0.41
Heart valve prosthesis 1/71 (1) 1/26 (4) 0.47
Antithrombotic drug history, n/N (%)y 48/71 (68) 15/26 (58) 0.36
Anticoagulantsy 26/71 (37) 7/26 (27) 0.37
Warfarin 14/71 (20) 6/26 (23) 0.72
LMWH 4/71 (6) 1/26 (4) 0.99
DOAC 9/71 (13) 0/26 0.11
Antiplateletsy 25/71 (35) 9/26 (35) 0.96
Acetylsalicylic acid, dipyridamole 21/71 (30) 9/26 (35) 0.63
Clopidogrel, ticagrelor 6/71 (8) 2/26 (8) 0.99
Admission mRS score, median (IQR) 3 (2e4) 4 (2e4) 0.99
Admission mRS score, n/N (%) 0.94
0 1/71 (1) 0/26
1 3/71 (4) 2/26 (8)
2 15/71 (21) 6/26 (23)
DVT, deep venous thrombosis; PE, pulmonary embolism; COPD, chronic obstructive pulmonary disease; LMWH, low molecular weight heparin; DOAC, direct oral anticoagulant; mRS, modified
Rankin Scale; IQR, interquartile range; NA not applicable.
*Medication used within 12 months.
yBefore detection of subdural hematoma.
zPatients treated with subdural drain unilaterally or bilaterally. Continues
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Supplementary Table 1. Continued
Variable Drain (N [ 71) Non-Drain (N [ 26) P Value
3 18/71 (25) 5/26 (19)
4 22/71 (31) 8/26 (31)
5 12/71 (17) 5/26 (19)
Preoperative hemiparesis, n/N (%) 34/71 (48) 5/25 (20) 0.015
Preoperative dysphasia, n/N (%) 26/71 (37) 6/26 (23) 0.21
Imaging characteristics
Side, n/N (%) 0.038
Left 21/71 (30) 15/26 (58)
Right 34/71 (48) 8/26 (31)
Bilateral 16/71 (23) 3/26 (12)
Total hematoma volume, cm3, median (IQR) 149 (99e170) 84 (62e120) <0.001
Basal cisterns open, n/N (%) 71/71 (100) 26/26 (100) NA
Unilateral N [ 55 N [ 23
Imaging characteristics
Hematoma density, n/N (%) 0.09
Hypodense 13/55 (24) 11/23 (48)
Isodense 9/55 (16) 1/23 (4)
Mixed 33/55 (60) 11/23 (48)
Midline shift, mm, median (IQR) 7 (3e10) 5 (2e7) 0.11
Hematoma thickness, mm, median (IQR) 23 (19e27) 15 (12e17) <0.001
Hematoma volume, cm3, median (IQR) 131 (86e157) 75 (62e116) <0.001
Cortical sulci, n/N (%) 0.038
Open 3/55 (5) 3/23 (13)
Compressed 6/55 (11) 7/23 (30)
Closed 46/55 (84) 13/23 (57)
Brain contusion, n/N (%) 0/55 1/23 (4) 0.29
Operation
Subdural fluid, n/N (%) 0.59
Clear 0/37 1/20 (5)
Straw 6/37 (16) 5/20 (25)
Engine oil 13/37 (35) 7/20 (35)
Fresh blood 8/37 (22) 4/20 (20)
Mixture 10/37 (27) 3/20 (15)
Subdural fluid pressure, n/N (%) 0.022
Low 6/53 (11) 9/23 (39)
Medium 31/53 (58) 8/23 (35)
High 16/53 (30) 6/23 (26)
Bilateral N [ 16z N [ 3
Imaging characteristics
Midline shift, mm, median (IQR) 0 (0e4) 3 (NA) 0.63
Continues
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Supplementary Table 1. Continued
Bilateral N [ 16z N [ 3
Side causing midline shift, n/N (%) 0.54
Left 4/16 (25) 2/3 (67)
Right 3/16 (19) 0/3
No midline shift 9/16 (56) 1/3 (33)
Total hematoma volume, cm3, median
(IQR)
186 (151
e241)
178 (NA) 0.71
Both sides separately N [ 27 N [ 11
Hematoma density, n/N (%) 0.59
Hypodense 5/27 (19) 3/11 (27)
Isodense 10/27 (37) 2/11 (18)
Mixed 12/27 (44) 6/11 (55)
Hematoma thickness, mm, median
(IQR)
19 (16e22) 15 (11e18) 0.049
Hematoma volume, cm3, median
(IQR)
100 (76
e123)
65 (51e84) 0.010
Cortical sulci, n/N (%) 0.41
Open 2/27 (7) 1/11 (9)
Compressed 9/27 (33) 6/11 (55)
Closed 16/27 (59) 4/11 (36)
Brain contusion, n/N 0/27 0/11 NA
Operation
Subdural fluid, n/N (%) 0.002
Clear 0/21 1/6 (17)
Straw 0/21 3/6 (50)
Engine oil 12/21 (57) 2/6 (33)
Fresh blood 2/21 (10) 0/6
Mixture 7/21 (33) 0/6
Subdural fluid pressure, n/N (%) 0.90
Low 6/25 (24) 3/11 (27)
Medium 12/25 (48) 6/11 (55)
High 7/25 (28) 2/11 (18)
DVT, deep venous thrombosis; PE, pulmonary embolism; COPD, chronic obstructive pulmonary disease; LMWH, low molecular weight heparin; DOAC, direct oral anticoagulant; mRS, modified
Rankin Scale; IQR, interquartile range; NA not applicable.
*Medication used within 12 months.
yBefore detection of subdural hematoma.
zPatients treated with subdural drain unilaterally or bilaterally.
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Supplementary Table 2. Postoperative Infections and Complications
Parameter Drain (N [ 71) Non-Drain (N [ 90) All Patients (N [ 161)
Infections within 1 month, n
Urinary tract infection 4 2 6
Pneumonia 1 5 6
Nonspecific infection 1 2 3
Pyelonephritis 1 1 2
Shingles 1 1
Soft tissue infection 1 1
All 8 11 19
Infections within 6 months, n*
Urinary tract infection 6 6 12
Pneumonia 3 7 10
Nonspecific infection 2 4 6
Upper respiratory infection 1 4 5
Pyelonephritis 2 2 4
Soft tissue infection 1 2 3
Erysipelas 2 2
Shingles 1 1
Gastroenteritis 1 1
All 18 26 44
Complications within 7 days, n
Cerebral infarction 2 2
Wound bleeding 2 2
Unintended drain removal 2 2
Intracerebral haemorrhage 1 1 2
Epileptic seizure 1 1 2
Pulmonary embolism 1 1
Epidural haematoma 1 1
Cardiac failure 1 1
All 8 5 13
*Missing for 34 of 161 patients (21%).
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